Search results

  1. Jonathan Edwards

    Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis, Bjornevik et al (2022)

    Can you give a reason for saying this? As far as I can see ATA 188 kills B cells, so if it works either explanation would fit. It doesn't look as if there are any firm data yet. The blurb looks fairly simplistic immunology to me. That does not mean that the drug will not work but I don't see...
  2. Jonathan Edwards

    Evaluation of a Multidisciplinary Integrated Treatment Approach Versus [SMC] for Functional Gastrointestinal Disorders (FGIDS), 2022, Bray et al

    This is an important point. Studies of treatments are only valuable if they are generalisable to new populations. 'Individualised, integrated multidisciplinary care' or whatever is by definition not generalisable, unless it invokes evidence-based indications as to who will benefit from which...
  3. Jonathan Edwards

    Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis, Bjornevik et al (2022)

    I think that is very unlikely. The presence of EBV in our B cells generally has no consequences. It just sits there. If it proliferates the B cell is killed. In all autoimmune diseases something else has happened to the B cell population that is not removed simply by temporary removal of EBV...
  4. Jonathan Edwards

    Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis, Bjornevik et al (2022)

    Ocrelizumab is essentially the same as rituximab. Its effect on MS probably has nothing to do with depleting EBV though, even if EBV is a necessary factor in genesis of the problem. The drugs remove the B cells that give rise to antibody-secreting plasma cells in brain. The problem about using...
  5. Jonathan Edwards

    New Clinical Phenotype of the Post-Covid Syndrome: Fibromyalgia and Joint Hypermobility Condition, 2022, Gavrilova et al

    Perhaps the 74 year old senior author feels a need to maintain his output of a paper a week over the last forty years (2,112).
  6. Jonathan Edwards

    Plasma metabolomics reveals disrupted response and recovery following maximal exercise in ME/CFS, Arnaud Germain, Maureen R. Hanson et al, 2022

    From what you say it seems there might be a big difference in mental state between patients and controls. And in hormonal responses over the 48 hour period and so on. Cortisol levels are likely to behave very differently, as well as adrenaline. Vagal control of respiration might well differ. And...
  7. Jonathan Edwards

    Plasma metabolomics reveals disrupted response and recovery following maximal exercise in ME/CFS, Arnaud Germain, Maureen R. Hanson et al, 2022

    OK I am beginning to remember half-understanding this. It seems that the change in work rate at ventilatory threshold could be affected by all sorts of shifts in neural control of the sort I was thinking of. So I am not sure why it should be interpreted as a metabolic phenomenon. One of the...
  8. Jonathan Edwards

    Plasma metabolomics reveals disrupted response and recovery following maximal exercise in ME/CFS, Arnaud Germain, Maureen R. Hanson et al, 2022

    The trouble is that this screws up any scientific analysis. PEM is a symptom pattern - as I understand it of feeling ill after exertion. If we then want to use the same word to mean what causes PEM we get PEM causes PEM and that opens things up to confusion. Maybe exertion releases some...
  9. Jonathan Edwards

    Plasma metabolomics reveals disrupted response and recovery following maximal exercise in ME/CFS, Arnaud Germain, Maureen R. Hanson et al, 2022

    I continue to be very puzzle by all this CPET stuff. I would like to get to grips with it but fail every time because of the jargon. If you have pain you may have a reduced ability to do work without altering utilisation of metabolic pathways. You put effort into protecting painful parts...
  10. Jonathan Edwards

    Evaluation of a Multidisciplinary Integrated Treatment Approach Versus [SMC] for Functional Gastrointestinal Disorders (FGIDS), 2022, Bray et al

    This means absolutely nothing. How can standards medical care be the one without the standardised approach? It is gibberish. I thought the whole point of multidisciplinary care was that it was person tailored and not standardised? How come there were two ways of treating patients at the same...
  11. Jonathan Edwards

    Plasma metabolomics reveals disrupted response and recovery following maximal exercise in ME/CFS, Arnaud Germain, Maureen R. Hanson et al, 2022

    I can see that but did they demonstrate a poorer performance to explain? If they didn't I don't see the point. There seems to me to be a confusion between PEM as defined as the symptom complex that occurs after exertion and PEM as defined as some fall in ability to do work - a sort of delayed...
  12. Jonathan Edwards

    Plasma metabolomics reveals disrupted response and recovery following maximal exercise in ME/CFS, Arnaud Germain, Maureen R. Hanson et al, 2022

    I continue to be puzzled by the interpretation of the 2 Day CPET in relation to PEM. I would have thought that anyone with ME who got PEM from the first maximal exercise would want to avoid a second one. If a feel lousy enough not to be able to carry on with normal daily activities I am pretty...
  13. Jonathan Edwards

    Who is Simon Wessely?

    My back is itching again.
  14. Jonathan Edwards

    Journal of Leukocyte Biology - Loss of mitochondrial membrane potential (ΔΨm) in leucocytes as post-COVID-19 sequelae, Díaz-Resendiz et al, 2022

    The abstract suggests that mitochondrial membrane potentials are down in leucocytes from people recovered from Covid so I fail to see the relevance to LongCovid?
  15. Jonathan Edwards

    Royal College of Psychiatrists apologising for saying things about PD patients that sound similar to what has been said about ME/CFS patients

    It's the same chatty, chummy style that has taken over RCPhysicians memos and BJGP, that creates patients as inconveniences.
  16. Jonathan Edwards

    Predictors for Developing Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome following Infectious Mononucleosis, 2022, Jason et al

    I think @Mithriel raises an important point here that maybe we have tended to gloss over. Prolonged fatigue after EBV is well recognised. I remember having it for about 6 months. That is not due to prolonged active replication of EBV. Control of viral proliferation occurs within the first few...
  17. Jonathan Edwards

    United Kingdom: Science Media Centre (including Fiona Fox)

    Jesus, my back is itching, isn't yours?
  18. Jonathan Edwards

    United Kingdom: Science Media Centre (including Fiona Fox)

    Just the latter I think. It is not surprising that there are lots of nice reviews. These are professional mutual backscratchers. More or less the circle of the Self-righteousness Marketing Company.
  19. Jonathan Edwards

    Implementation statement in support of ME/CFS diagnosis and management, NICE, draft published for consultation

    This was the response letter to NICE: Dear Heather, Thanks for the implementation document draft. I have consulted with the S4ME committee and would like to convey the following comments: Much of the implementation statement looks appropriate and we would support. Several issues came to our...
  20. Jonathan Edwards

    The biological challenge of myalgic encephalomyelitis/chronic fatigue syndrome: a solvable problem (2016), Edwards, JC et al

    Absolutely. That is what I mean by trying to find out what is going on - cause and effect.
Back
Top Bottom